Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Addressing a complicated problem: can COVID-19 asymptomatic cases be detected – and epidemics stopped− when testing is limited and the location of such cases unknown?

View ORCID ProfileAriel L. Rivas, Almira L. Hoogesteijn, James B. Hittner, View ORCID ProfileFolorunso O. Fasina, View ORCID ProfileMarc H.V. van Regenmortel
doi: https://doi.org/10.1101/2020.11.10.20223495
Ariel L. Rivas
1Center for Global Health, Department of Internal Medicine, Medical School, University of New Mexico, Albuquerque, New Mexico, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ariel L. Rivas
Almira L. Hoogesteijn
2Human Ecology, Centro de Investigacion y de Estudios Avanzados (CINVESTAV), Merida, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James B. Hittner
3Department of Psychology, College of Charleston, Charleston, South Carolina, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Folorunso O. Fasina
4Food and Agriculture Organization, Dar es Salam, Tanzania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Folorunso O. Fasina
  • For correspondence: daydupe2003@yahoo.co.uk
Marc H.V. van Regenmortel
5University of Vienna, Austria; and Higher School of Biotechnology, University of Strasbourg, 11, France & French National Research Center (CNRS), France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc H.V. van Regenmortel
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Can the COVID-19 pandemic be stopped when the principal disseminators −asymptomatic cases− are not easily observable? This question was addressed exploring the cumulative epidemiologic data reported by 51 countries, up to October 2, 2020. In particular, the validity of test positivity and its inverse (the ratio of tests performed per case detected) to indicate whether asymptomatic cases are being detected and isolated –even when only a minor percentage of the population is tested− was evaluated. By linking test positivity data to the number of COVID-19 related deaths reported per million inhabitants, the research question was answered: countries that expressed a high percentage of test positivity (>5%) reported, on average, 15 times more deaths than countries that exhibited <1% test positivity. It is suggested that such a large difference in outcomes is due to the exponential growth that epidemics may experience when silent (asymptomatic) cases are not detected and, consequently, the disease disseminates. Because temporal and geo-referenced data on test positivity may facilitate cost-effective, site-specific testing policies, it is postulated that the risk of uncontrolled epidemics may be ameliorated when test positivity is investigated.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

This is an observational study based on open-sourced dataset.

Funding Statement

No funding was obtained for this research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was based on open-access datasets. Hence no oversight function was needed by the Institutional oversight committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are publically available.

https://ourworldindata.org/coronavirus-testing#how-many-tests-are-performed-each-day

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 13, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Addressing a complicated problem: can COVID-19 asymptomatic cases be detected – and epidemics stopped− when testing is limited and the location of such cases unknown?
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Addressing a complicated problem: can COVID-19 asymptomatic cases be detected – and epidemics stopped− when testing is limited and the location of such cases unknown?
Ariel L. Rivas, Almira L. Hoogesteijn, James B. Hittner, Folorunso O. Fasina, Marc H.V. van Regenmortel
medRxiv 2020.11.10.20223495; doi: https://doi.org/10.1101/2020.11.10.20223495
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Addressing a complicated problem: can COVID-19 asymptomatic cases be detected – and epidemics stopped− when testing is limited and the location of such cases unknown?
Ariel L. Rivas, Almira L. Hoogesteijn, James B. Hittner, Folorunso O. Fasina, Marc H.V. van Regenmortel
medRxiv 2020.11.10.20223495; doi: https://doi.org/10.1101/2020.11.10.20223495

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (525)
  • Anesthesia (125)
  • Cardiovascular Medicine (1434)
  • Dentistry and Oral Medicine (220)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10330)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2653)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (681)
  • Hematology (269)
  • HIV/AIDS (570)
  • Infectious Diseases (except HIV/AIDS) (12119)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (276)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2483)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (497)
  • Occupational and Environmental Health (569)
  • Oncology (1333)
  • Ophthalmology (403)
  • Orthopedics (152)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (345)
  • Pediatrics (786)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (297)
  • Psychiatry and Clinical Psychology (2419)
  • Public and Global Health (5031)
  • Radiology and Imaging (901)
  • Rehabilitation Medicine and Physical Therapy (536)
  • Respiratory Medicine (688)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)